China climbed biotech's worry list, while Big Pharma kept shopping
In the months leading up to the Treasury Department's release of draft rules that would limit US investment in Chinese biopharma, the industry's view of China was already in a downward sentiment ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.